IGF2 and hepatoblastoma: Hepatoblastoma development has been associated with UPD (4.7%, P < 0.001) (Mussa et al., 2016a) although it is also observed in patients with KCNQ1OT1:TSS-DMR-LOM (0.7%) and H19/IGF2:IG-DMR -GOM (0.8%, P < 0.001).